Comparison of the Clinical Characteristics and Outcome of Benign and Malignant Eyelid Tumors: An Analysis of 4521 Eyelid Tumors in a Tertiary Medical Center
Table 2
The demographic data, clinical features, treatment, and outcome of malignant eyelid tumors.
Malignant eyelid tumors ()
Number (%)
Gender (M/F)
Mean age
(years, range)
Laterality (R/L/B)
Location (U/L/B)
Adjunct treatment
Recurrence
Mortality
Chemo/radiation/CCRT
Exenteration/enucleation
Number (%)
Number (%)
Basal cell carcinoma
131 (57.8%)
90/41
72.5
(21–93)
55/64/3
25/90/0
0/0/0
1/0
8 (6.1%)
0 (0%)
Sebaceous gland carcinoma
48 (21.1%)
20/28
74.1
(44–91)
23/25/0
27/19/1
0/3/0
5/0
10 (20.8%)
1 (2.1%)
Squamous cell carcinoma
23 (10.1%)
16/7
71.7
(40–93)
8/15/0
7/6/0
0/0/4
2/2
7 (30.4%)
3 (13.0%)
Melanoma
8 (3.5%)
6/2
67.4
(21–84)
2/6/0
3/2/0
1/0/0
5/0
0 (0%)
2 (25.0%)
Adenocarcinoma
5 (2.2%)
4/1
73.8
(64–88)
1/4/0
0/1/0
0/1/1
3/0
0 (0%)
1 (20%)
Adenoid cystic carcinoma
2 (0.9%)
0/2
53.0
(47–59)
1/1/0
1/0/0
0/2/0
2/0
1 (50%)
0 (0%)
Others
10 (4.4%)
8/2
71.7
(46–90)
5/4/0
5/1/0
1/1/1
2/0
1 (10%)
1 (10%)
Total number not equal to 100% of cases because of incomplete chart information or data missing. Others including small cell carcinoma, epidermoid carcinoma, merkel cell carcinoma, B-cell lymphoma, T-cell lymphoma, lymphoepithelial carcinoma, invasive nonkeratinizing carcinoma, myeloid sarcoma, angiosarcoma, and malignant proliferating pilar tumor.
